0001209191-20-054255.txt : 20201007
0001209191-20-054255.hdr.sgml : 20201007
20201007212825
ACCESSION NUMBER: 0001209191-20-054255
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201005
FILED AS OF DATE: 20201007
DATE AS OF CHANGE: 20201007
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vuori Kristiina MD
CENTRAL INDEX KEY: 0001612627
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 201230007
MAIL ADDRESS:
STREET 1: C/O WEBMD HEALTH CORP.
STREET 2: 111 EIGHTH AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10011
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axovant Gene Therapies Ltd.
CENTRAL INDEX KEY: 0001636050
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981333697
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 11-12 ST. JAMES'S SQUARE
STREET 2: SUITE 1, 3RD FLOOR
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: 44 203 318 9708
MAIL ADDRESS:
STREET 1: 11 TIMES SQUARE
STREET 2: 33RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences Ltd.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences, Inc.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Roivant Neurosciences Ltd.
DATE OF NAME CHANGE: 20150309
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-05
0
0001636050
Axovant Gene Therapies Ltd.
AXGT
0001612627
Vuori Kristiina MD
C/O AXOVANT GENE THERAPIES LTD.
11 TIMES SQUARE, 33RD FLOOR
NEW YORK
NY
10036
1
0
0
0
Stock Option (Right to Buy)
5.63
2020-10-05
4
A
0
35000
0.00
A
2030-10-04
Common Stock
35000
35000
D
The common shares underlying this option vest over a period of three years, with one-third of the common shares vesting on each of the first, second and third anniversaries of October 5, 2020, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.
/s/ David Nassif, Attorney-In-Fact
2020-10-07